Tumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumab

Histochemistry and Cell Biology

Volumn 137, Issue 3, 2012, Pages 391-401

  Weihardt, Philip ^a   Trarbach, Tanja ^a   Dürig, Jan ^a   Paul, Andreas ^a   Reis, Henning ^a   Tilki, Derya ^b   Miroschnik, Inna ^a   Ergün, Süleyman ^a   Klein, Diana ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Anti angiogenic therapy; Bevacizumab; Pericytes; Smooth muscle cell; Vascular stabilization

Indexed keywords

ANGIOGENIC FACTOR; BEVACIZUMAB;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; APOPTOSIS; ARTICLE; CANCER RECURRENCE; CARCINOMA CELL; CELL DIFFERENTIATION; CELL STRUCTURE; COLORECTAL CARCINOMA; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MUSCLE, SMOOTH, VASCULAR; NEOVASCULARIZATION, PATHOLOGIC; PERICYTES; PROSTATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; MUS;

EID: 84857630253     PISSN: 09486143     EISSN: 1432119X     Source Type: Journal    
DOI: 10.1007/s00418-011-0898-8     Document Type: Article

References (40)

1. LE Benjamin I Hemo E Keshet 1998 A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF Development 125 1591 1598 9521897 1:CAS:528:DyaK1cXjslemsLg%3D (Pubitemid 28256727)
2. LE Benjamin D Golijanin A Itin D Pode E Keshet 1999 Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal J Clin Invest 103 159 165 9916127 10.1172/JCI5028 1:CAS:528:DyaK1MXltFeruw%3D%3D (Pubitemid 29053133)
3. R Erber A Thurnher AD Katsen G Groth H Kerger HP Hammes MD Menger A Ullrich P Vajkoczy 2004 Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms FASEB J 18 338 340 14657001 1:CAS:528:DC%2BD2cXht1Gjtrg%3D
4. S Ergün N Kilic JH Wurmbach A Ebrahimnejad M Fernando S Sevinc E Kilic F Chalajour W Fiedler H Lauke K Lamszus P Hammerer J Weil H Herbst J Folkman 2001 Endostatin inhibits angiogenesis by stabilization of newly formed endothelial tubes Angiogenesis 4 193 206 11911017 10.1023/A:1014027218980 (Pubitemid 34174308)
5. S Ergün D Tilki L Oliveira-Ferrer G Schuch N Kilic 2006 Significance of vascular stabilization for tumor growth and metastasis Cancer Lett 238 180 187 16084013 10.1016/j.canlet.2005.06.033 (Pubitemid 43867907)
6. S Ergün HP Hohn N Kilic BB Singer D Tilki 2008 Endothelial and hematopoietic progenitor cells (EPCs and HPCs): hand in hand fate determining partners for cancer cells Stem Cell Rev 4 169 177 18607782 10.1007/s12015-008- 9028-y
7. N Ferrara KJ Hillan W Novotny 2005 Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy Biochem Biophys Res Commun 333 328 335 15961063 10.1016/j.bbrc.2005.05.132 1:CAS:528:DC%2BD2MXlsVChtLs%3D (Pubitemid 40848295)
8. K Gaengel G Genové A Armulik C Betsholtz 2009 Endothelial-mural cell signaling in vascular development and angiogenesis Arterioscler Thromb Vasc Biol 29 630 638 19164813 10.1161/ATVBAHA.107.161521 1:CAS:528: DC%2BD1MXktF2qtb4%3D
9. MS Gee WN Procopio S Makonnen MD Feldman NM Yeilding WM Lee 2003 Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy Am J Pathol 162 183 193 12507901 10.1016/S0002-9440(10) 63809-6 (Pubitemid 36042000)
10. V Goede O Coutelle J Neuneier A Reinacher-Schick R Schnell TC Koslowsky MR Weihrauch B Cremer H Kashkar M Odenthal HG Augustin W Schmiegel M Hallek UT Hacker 2010 Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy Br J Cancer 103 1407 1414 20924372 10.1038/sj.bjc.6605925 1:CAS:528:DC%2BC3cXhtlCjs7fK
11. JI Greenberg DJ Shields SG Barillas LM Acevedo E Murphy J Huang L Scheppke C Stockmann RS Johnson N Angle DA Cheresh 2008 A role for VEGF as a negative regulator of pericyte function and vessel maturation Nature 456 809 813 18997771 10.1038/nature07424 1:CAS:528:DC%2BD1cXhsVymt77I
12. Y Hasumi A Kłosowska-Wardega M Furuhashi A Ostman CH Heldin C Hellberg 2007 Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling Int J Cancer 121 2606 2614 17691110 10.1002/ijc.22999 1:CAS:528:DC%2BD2sXhtl2qsLzF (Pubitemid 350136402)
13. VL Heath R Bicknell 2009 Anticancer strategies involving the vasculature Nat Rev Clin Oncol 6 395 404 19424102 10.1038/nrclinonc.2009.52 1:CAS:528:DC%2BD1MXnslKks78%3D
14. I Helfrich D Schadendorf 2011 Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: one step forward for overcoming anti-angiogenic drug resistance? Mol Oncol 5 137 149 21345752 10.1016/j.molonc.2011.01.003 1:CAS:528:DC%2BC3MXlsFWrsb0%3D
15. I Helfrich I Scheffrahn S Bartling J Weis V von Felbert M Middleton M Kato S Ergün D Schadendorf 2010 Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma J Exp Med 207 491 503 20194633 10.1084/jem.20091846 1:CAS:528:DC%2BC3cXjvVOhsL0%3D
16. RK Jain 2001 Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy Nat Med 7 987 989 11533692 10.1038/nm0901-987 1:CAS:528:DC%2BD3MXmvFOmsrc%3D (Pubitemid 32937367)
17. RK Jain 2005 Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307 58 62 15637262 10.1126/science.1104819 1:CAS:528:DC%2BD2MXnvFar (Pubitemid 40093472)
18. MR Kano Y Komuta C Iwata M Oka YT Shirai Y Morishita Y Ouchi K Kataoka K Miyazono 2009 Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature Cancer Sci 100 173 180 19037999 10.1111/j.1349-7006.2008.01003.x 1:CAS:528:DC%2BD1MXhtlGnsb0%3D
19. D Klein A Demory F Peyre J Kroll HG Augustin W Helfrich J Kzhyshkowska K Schledzewski B Arnold S Goerdt 2008 Wnt2 acts as a cell type-specific, autocrine growth factor in rat hepatic sinusoidal endothelial cells cross-stimulating the VEGF pathway Hepatology 47 1018 1031 18302287 10.1002/hep.22084 1:CAS:528:DC%2BD1cXktVOhsb8%3D (Pubitemid 351449693)
20. D Klein A Demory F Peyre J Kroll C Géraud N Ohnesorge K Schledzewski B Arnold S Goerdt 2009 Wnt2 acts as an angiogenic growth factor for non-sinusoidal endothelial cells and inhibits expression of stanniocalcin-1 Angiogenesis 12 251 265 19444628 10.1007/s10456-009-9145-5 1:CAS:528: DC%2BD1MXhtFOktrvK
21. D Klein P Weihardt V Kleff H Jastrow HG Jakob S Ergün 2011 Vascular wall-resident cd44+ multipotent stem cells give rise to pericytes and smooth muscle cells and contribute to new vessel maturation PLoS One 6 e20540 21637782 10.1371/journal.pone.0020540 1:CAS:528:DC%2BC3MXntVait7g%3D
22. S Lee 2010 What tumor vessels can tell us Pigment Cell Melanoma Res 23 309 311 20403121 10.1111/j.1755-148X.2010.00706.x
23. MI Lin WC Sessa 2004 Antiangiogenic therapy: creating a unique "window" of opportunity Cancer Cell 6 529 531 15607955 1:CAS:528:DC%2BD2MXktVansg%3D%3D (Pubitemid 40017694)
24. S Morikawa P Baluk T Kaidoh A Haskell RK Jain DM McDonald 2002 Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors Am J Pathol 160 985 1000 11891196 10.1016/S0002-9440(10)64920-6 (Pubitemid 34224587)
25. K Mulder A Scarfe N Chua J Spratlin 2011 The role of bevacizumab in colorectal cancer: understanding its benefits and limitations Expert Opin Biol Ther 11 405 413 21281258 10.1517/14712598.2011.557657 1:CAS:528: DC%2BC3MXhs1yksrk%3D
26. V Nehls K Denzer D Drenckhahn 1992 Pericyte involvement in capillary sprouting during angiogenesis in situ Cell Tissue Res 270 469 474 1283113 10.1007/BF00645048 1:STN:280:DyaK3s7jslaruw%3D%3D
27. DM Neskey A Ambesi KM Pumiglia PJ McKeown-Longo 2008 Endostatin and anastellin inhibit distinct aspects of the angiogenic process J Exp Clin Cancer Res 27 61 18983664 10.1186/1756-9966-27-61
28. RF Nicosia S Villaschi 1999 Autoregulation of angiogenesis by cells of the vessel wall Int Rev Cytol 185 1 43 9750264 10.1016/S0074-7696(08)60148-5 1:CAS:528:DyaK1MXlsVWl (Pubitemid 129751071)
29. U Ozerdem WB Stallcup 2003 Early contribution of pericytes to angiogenic sprouting and tube formation Angiogenesis 6 241 249 15041800 10.1023/B:AGEN.0000021401.58039.a9 1:CAS:528:DC%2BD2cXisVKrtrg%3D (Pubitemid 38506669)
30. JN Passman XR Dong SP Wu CT Maguire KA Hogan VL Bautch MW Majesky 2008 A sonic hedgehog signaling domain in the arterial adventitia supports resident Sca1+ smooth muscle progenitor cells Proc Natl Acad Sci USA 105 9349 9354 18591670 10.1073/pnas.0711382105 1:CAS:528:DC%2BD1cXosFars74%3D
31. A Puthillath A Patel MG Fakih 2009 Targeted therapies in the management of colorectal carcinoma: role of bevacizumab Onco Targets Ther 2 1 15 20616890 1:CAS:528:DC%2BD1MXpt1yqtrk%3D
32. G Ranieri R Patruno E Ruggieri S Montemurro P Valerio D Ribatti 2006 Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic Curr Med Chem 13 1845 1857 16842197 10.2174/092986706777585059 1:CAS:528:DC%2BD28Xms1CltrY%3D
33. A Raza MJ Franklin AZ Dudek 2010 Pericytes and vessel maturation during tumor angiogenesis and metastasis Am J Hematol 85 593 598 20540157 10.1002/ajh.21745 1:CAS:528:DC%2BC3cXhtV2ntrbM
34. Y Sato 2003 Molecular diagnosis of tumor angiogenesis and anti-angiogenic cancer therapy Int J Clin Oncol 8 200 206 12955574 10.1007/s10147-003-0342-8 1:CAS:528:DC%2BD3sXmvVajsLk%3D (Pubitemid 37122254)
35. S Song AJ Ewald W Stallcup Z Werb G Bergers 2005 PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival Nat Cell Biol 7 870 879 16113679 10.1038/ncb1288 1:CAS:528: DC%2BD2MXpslaksb4%3D (Pubitemid 41486287)
36. U Tigges EG Hyer J Scharf WB Stallcup 2008 FGF2-dependent neovascularization of subcutaneous Matrigel plugs is initiated by bone marrow-derived pericytes and macrophages Development 135 523 532 18171688 10.1242/dev.002071 1:CAS:528:DC%2BD1cXjt1Cnt78%3D
37. D Tilki N Kilic S Sevinc F Zywietz CG Stief S Ergun 2007 Zone-specific remodeling of tumor blood vessels affects tumor growth Cancer 110 2347 2362 17849463 10.1002/cncr.23024 1:CAS:528:DC%2BD2sXhsVWrtbrI (Pubitemid 350100758)
38. D Virgintino F Girolamo M Errede C Capobianco D Robertson WB Stallcup R Perris L Roncali 2007 An intimate interplay between precocious, migrating pericytes and endothelial cells governs human fetal brain angiogenesis Angiogenesis 10 35 45 17225955 10.1007/s10456-006-9061-x (Pubitemid 46356222)
39. P Wesseling RO Schlingemann FJ Rietveld M Link PC Burger DJ Ruiter 1995 Early and extensive contribution of pericytes/vascular smooth muscle cells to microvascular proliferation in glioblastoma multiforme: an immuno-light and immuno-electron microscopic study J Neuropathol Exp Neurol 54 304 310 7745429 10.1097/00005072-199505000-00003 1:STN:280:DyaK2M3msVWmug%3D%3D
40. E Zengin F Chalajour UM Gehling WD Ito H Treede H Lauke, et al. 2006 Vascular wall resident progenitor cells: a source for postnatal vasculogenesis Development 133 1543 1551 16524930 10.1242/dev.02315 1:CAS:528: DC%2BD28XltVamsLs%3D (Pubitemid 43732967)